SCHEMBL12490205

SCHEMBL12490205

OCc1ccc(C(F)(F)C2CC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.36
TAAR1 Q96RJ0 1/20 0.35
TSHR P16473 1/20 0.34
PTPN2 P17706 1/20 0.34
PTPN1 P18031 1/20 0.34
PTPN6 P29350 1/20 0.34
PTPN11 Q06124 1/20 0.34
TRPM8 Q7Z2W7 2/20 0.33
EPHX2 P34913 1/20 0.33
NR1I2 O75469 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
GAA P10253 1/20 0.33
MAOB P27338 1/20 0.33
CHKA P35790 1/20 0.32
PRSS1 P07477 1/20 0.32
PRSS2 P07478 1/20 0.32
PRSS3 P35030 1/20 0.32
KDM4E B2RXH2 2/20 0.32
DDB1 Q16531 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12490702 0.92 TRPM8 (0.35) KIF11TAAR1TSHRPTPN2PTPN1
SCHEMBL12490411 0.79 AR (0.47) KIF11TRPM8NR1I2
SCHEMBL29009836 0.78 RXRA (0.49) TSHREPHX2GAA
SCHEMBL12490311 0.78 PRKCA (0.41) TAAR1TRPM8GAAKDM4E
SCHEMBL29009745 0.74 SMN1; SMN2 (0.51) TSHRPTPN2PTPN1PTPN6PTPN11
SCHEMBL96239 0.73 TAAR1 (0.54) KIF11TAAR1MAOBKDM4E
SCHEMBL12490260 0.73 KIF11 (0.49) KIF11TRPM8
SCHEMBL12490248 0.73 KIF11 (0.41) KIF11TRPM8
SCHEMBL23536023 0.72 CYP19A1 (0.44) MAOB
SCHEMBL15437156 0.72 TAAR1 (0.59) TAAR1MAOBCHKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9540360-B2 Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-10 US disclosed
US-9540360-B2 Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-10 US disclosed
US-9540360-B2 Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-10 US disclosed
EP-2686302-B1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY MITSUBISHI TANABE PHARMA CORP (JP) 2016-08-10 EP disclosed
EP-2686302-B1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY MITSUBISHI TANABE PHARMA CORP (JP) 2016-08-10 EP disclosed
US-20150218143-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-08-06 US disclosed
US-20150218143-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-08-06 US disclosed
US-20150218143-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-08-06 US disclosed
US-8987445-B2 Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-24 US disclosed
US-8987445-B2 Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-24 US disclosed
US-8987445-B2 Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-24 US disclosed
EP-2686302-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY Mitsubishi Tanabe Pharma Corporation (JP) 2014-01-22 EP disclosed
US-20140005393-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY KALLYOPE, INC. 2014-01-02 US disclosed
WO-2012124825-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-09-20 WO disclosed
WO-2012124825-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218143-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY TRPM8, TRPM7, TRPM2 KIF11 3307/4885TAAR1 1594/4885TSHR 2048/4885
US-20140005393-A1 SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY TRPM8, TRPM7, TRPM2 KIF11 3408/4885TAAR1 1601/4885TSHR 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.